A reversible monoamine oxidase a inhibitor, befloxatone

Structural approach of its mechanism of action

Johan Wouters, Florence Moureau, Guy Evrard, Jean Jacques Koenig, Samir Jegham, Pascal George, François Durant

Research output: Contribution to journalArticle

Abstract

Experimental and theoretical physico-chemical methods were used to investigate the interaction between several reversible monoamine oxidase A inhibitors in the oxazolidinone series and the active site of the enzyme. Phenyloxazolidinones include toloxatone and analogues, among which befloxatone was selected as drug candidate for the treatment of depression. Identification of the forces responsible for the crystal cohesion of befloxatone reveals functional groups that could interact with monoamine oxidase. Calculation of electronic properties of those compounds using ab initio molecular orbital methods lead to a description of the mode of interaction between befloxatone and the cofactor of the enzyme. Electronic absorption spectroscopy measurements confirm the hypothesis of a privileged interaction of phenyloxazolidinone-type inhibitors with the flavin cofactor of MAO. Additional sites of interaction with the protein core of MAO A are also examined with regard to the primary structure of the enzyme. As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site. This model is partially corroborated by experimental evidence and should be helpful in designing new potent inhibitors of monoamine oxidase. Copyright (C) 1999 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)1683-1693
Number of pages11
JournalBioorganic and Medicinal Chemistry
Volume7
Issue number8
DOIs
Publication statusPublished - 1 Aug 1999

Fingerprint

Monoamine Oxidase Inhibitors
Monoamine Oxidase
Coenzymes
Catalytic Domain
Oxazolidinones
Flavin-Adenine Dinucleotide
Molecular orbitals
Enzymes
Absorption spectroscopy
Electronic properties
Functional groups
Spectrum Analysis
befloxatone
Amino Acids
Crystals
Pharmaceutical Preparations
Proteins

Keywords

  • Befloxatone
  • Enzyme inhibitors
  • Monoamine oxidase
  • X-ray crystal structures

Cite this

Wouters, Johan ; Moureau, Florence ; Evrard, Guy ; Koenig, Jean Jacques ; Jegham, Samir ; George, Pascal ; Durant, François. / A reversible monoamine oxidase a inhibitor, befloxatone : Structural approach of its mechanism of action. In: Bioorganic and Medicinal Chemistry. 1999 ; Vol. 7, No. 8. pp. 1683-1693.
@article{530b08d5ff5e43669074f6cac5a1e771,
title = "A reversible monoamine oxidase a inhibitor, befloxatone: Structural approach of its mechanism of action",
abstract = "Experimental and theoretical physico-chemical methods were used to investigate the interaction between several reversible monoamine oxidase A inhibitors in the oxazolidinone series and the active site of the enzyme. Phenyloxazolidinones include toloxatone and analogues, among which befloxatone was selected as drug candidate for the treatment of depression. Identification of the forces responsible for the crystal cohesion of befloxatone reveals functional groups that could interact with monoamine oxidase. Calculation of electronic properties of those compounds using ab initio molecular orbital methods lead to a description of the mode of interaction between befloxatone and the cofactor of the enzyme. Electronic absorption spectroscopy measurements confirm the hypothesis of a privileged interaction of phenyloxazolidinone-type inhibitors with the flavin cofactor of MAO. Additional sites of interaction with the protein core of MAO A are also examined with regard to the primary structure of the enzyme. As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site. This model is partially corroborated by experimental evidence and should be helpful in designing new potent inhibitors of monoamine oxidase. Copyright (C) 1999 Elsevier Science Ltd.",
keywords = "Befloxatone, Enzyme inhibitors, Monoamine oxidase, X-ray crystal structures",
author = "Johan Wouters and Florence Moureau and Guy Evrard and Koenig, {Jean Jacques} and Samir Jegham and Pascal George and Fran{\cc}ois Durant",
year = "1999",
month = "8",
day = "1",
doi = "10.1016/S0968-0896(99)00102-9",
language = "English",
volume = "7",
pages = "1683--1693",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "8",

}

A reversible monoamine oxidase a inhibitor, befloxatone : Structural approach of its mechanism of action. / Wouters, Johan; Moureau, Florence; Evrard, Guy; Koenig, Jean Jacques; Jegham, Samir; George, Pascal; Durant, François.

In: Bioorganic and Medicinal Chemistry, Vol. 7, No. 8, 01.08.1999, p. 1683-1693.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A reversible monoamine oxidase a inhibitor, befloxatone

T2 - Structural approach of its mechanism of action

AU - Wouters, Johan

AU - Moureau, Florence

AU - Evrard, Guy

AU - Koenig, Jean Jacques

AU - Jegham, Samir

AU - George, Pascal

AU - Durant, François

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Experimental and theoretical physico-chemical methods were used to investigate the interaction between several reversible monoamine oxidase A inhibitors in the oxazolidinone series and the active site of the enzyme. Phenyloxazolidinones include toloxatone and analogues, among which befloxatone was selected as drug candidate for the treatment of depression. Identification of the forces responsible for the crystal cohesion of befloxatone reveals functional groups that could interact with monoamine oxidase. Calculation of electronic properties of those compounds using ab initio molecular orbital methods lead to a description of the mode of interaction between befloxatone and the cofactor of the enzyme. Electronic absorption spectroscopy measurements confirm the hypothesis of a privileged interaction of phenyloxazolidinone-type inhibitors with the flavin cofactor of MAO. Additional sites of interaction with the protein core of MAO A are also examined with regard to the primary structure of the enzyme. As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site. This model is partially corroborated by experimental evidence and should be helpful in designing new potent inhibitors of monoamine oxidase. Copyright (C) 1999 Elsevier Science Ltd.

AB - Experimental and theoretical physico-chemical methods were used to investigate the interaction between several reversible monoamine oxidase A inhibitors in the oxazolidinone series and the active site of the enzyme. Phenyloxazolidinones include toloxatone and analogues, among which befloxatone was selected as drug candidate for the treatment of depression. Identification of the forces responsible for the crystal cohesion of befloxatone reveals functional groups that could interact with monoamine oxidase. Calculation of electronic properties of those compounds using ab initio molecular orbital methods lead to a description of the mode of interaction between befloxatone and the cofactor of the enzyme. Electronic absorption spectroscopy measurements confirm the hypothesis of a privileged interaction of phenyloxazolidinone-type inhibitors with the flavin cofactor of MAO. Additional sites of interaction with the protein core of MAO A are also examined with regard to the primary structure of the enzyme. As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site. This model is partially corroborated by experimental evidence and should be helpful in designing new potent inhibitors of monoamine oxidase. Copyright (C) 1999 Elsevier Science Ltd.

KW - Befloxatone

KW - Enzyme inhibitors

KW - Monoamine oxidase

KW - X-ray crystal structures

UR - http://www.scopus.com/inward/record.url?scp=0032802065&partnerID=8YFLogxK

U2 - 10.1016/S0968-0896(99)00102-9

DO - 10.1016/S0968-0896(99)00102-9

M3 - Article

VL - 7

SP - 1683

EP - 1693

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 8

ER -